> ⚠️ Research Use Only Disclaimer: This article is intended for research purposes only. Retatrutide (LY3437943) is an investigational compound currently in Phase 3 clinical trials. It has not been approved by the FDA or any regulatory body for human therapeutic use. This information is provided for educational and scientific research purposes only. Not for human use. Consult qualified medical personnel for any health-related decisions.
# Retatrutide Dosage Protocol Guide: Triple GLP-1/GIP/Glucagon Agonist Research 2026
Retatrutide (LY3437943) represents the next frontier in metabolic peptide research. As a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide has demonstrated unprecedented efficacy in Phase 2 clinical trials — including a landmark 24.2% mean body weight reduction over 48 weeks, surpassing any previously studied compound in this class.
For researchers studying metabolic pathways, obesity mechanisms, and next-generation therapeutic candidates, understanding retatrutide's pharmacology and trial-derived dosing protocols is essential. This guide provides a comprehensive overview of retatrutide's research dosage protocols based on published Phase 2 trial data and ongoing Phase 3 trial design.
For research purposes only. Not for human use.
---
What Is Retatrutide? Triple Agonist Mechanism
Retatrutide (development code: LY3437943) is a synthetic peptide developed by Eli Lilly and Company. Unlike its predecessors in the incretin-mimetic class, retatrutide uniquely activates three distinct hormone receptors:
- •GLP-1 receptor (GLP-1R): Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite
- •GIP receptor (GIPR): Enhances insulin secretion, improves insulin sensitivity, modulates adipose tissue metabolism and energy expenditure
- •Glucagon receptor (GCGR): Increases energy expenditure, promotes fat oxidation and hepatic glucose output modulation
This tri-agonist mechanism creates a synergistic effect beyond what dual-agonists like tirzepatide achieve. The glucagon receptor component — controversial in earlier research for its glucose-raising potential — is now understood to enhance thermogenesis and energy expenditure when balanced against the insulin-stimulating effects of GLP-1R and GIPR activation.
Molecular characteristics:
- •INN: Retatrutide
- •Development code: LY3437943
- •Molecular class: Synthetic acylated peptide
- •Primary mechanism: Triple incretin/glucagon receptor agonism
- •Half-life: ~6–7 days (enabling once-weekly dosing)
- •Administration route: Subcutaneous injection
For a deeper exploration of retatrutide's molecular pharmacology, see our companion guide: Retatrutide (LY3437943): Triple Hormone Receptor Agonist — Complete Research Profile.
For research purposes only. Not for human use.
---
Research Dosage Protocols: Phase 2 Trial Data
The most reliable dosage data for retatrutide comes from the landmark Phase 2 TRIUMPH trial (Jastreboff et al., NEJM 2023), which evaluated multiple dose levels in 338 adults with obesity (BMI ≥27) without type 2 diabetes over 48 weeks.
Phase 2 Dosing Cohorts
The trial tested the following weekly subcutaneous injection protocols:
| Dose Level | Escalation Schedule | Final Dose | 48-Week Weight Loss |
|---|---|---|---|
| 1 mg | Start 1 mg, maintain | 1 mg/week | ~8.7% |
| 4 mg | Escalate over 8 weeks to 4 mg | 4 mg/week | ~17.1% |
| 8 mg | Escalate over 16 weeks to 8 mg | 8 mg/week | ~22.8% |
| 12 mg | Escalate over 24 weeks to 12 mg | 12 mg/week | ~24.2% |
Key finding: The 12 mg cohort demonstrated 24.2% mean body weight reduction at 48 weeks — the highest efficacy reported for any anti-obesity compound in peer-reviewed Phase 2 trials as of publication date.
Standard Escalation Protocol (Research Reference)
Based on Phase 2 trial design, the escalation schedule for the maximum-dose cohort proceeded as follows:
Weeks 1–4: 2 mg once weekly
Weeks 5–8: 4 mg once weekly
Weeks 9–12: 4 mg once weekly
Weeks 13–16: 6 mg once weekly
Weeks 17–20: 8 mg once weekly
Weeks 21–24: 10 mg once weekly
Weeks 25–48: 12 mg once weekly (maintenance)
Rationale for gradual escalation: The slow escalation schedule minimizes gastrointestinal adverse effects (nausea, vomiting), which are dose-dependent and peak during the up-titration phase. Trial data showed GI events substantially decreased after each new dose level was maintained for 2–4 weeks.
For research purposes only. Not for human use.
---
Phase 3 Trial Design: TRIUMPH Phase 3
The ongoing Phase 3 TRIUMPH program (ClinicalTrials.gov: NCT04867590) is evaluating retatrutide across multiple populations:
- •TRIUMPH-1: Adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related comorbidity)
- •TRIUMPH-2: Adults with type 2 diabetes and obesity
- •TRIUMPH-3: Cardiovascular outcomes trial
Phase 3 dose levels under investigation: 4 mg, 8 mg, and 12 mg once weekly
Primary endpoint: Percent change from baseline body weight at 72 weeks
Phase 3 trial status: Ongoing (as of 2026); Eli Lilly has reported enrollment completion
The Phase 3 protocol maintains the same escalation approach established in Phase 2, validating the dose-escalation paradigm as the standard research framework.
For research purposes only. Not for human use.
---
Reconstitution Guide
Retatrutide for research is typically available as lyophilized (freeze-dried) powder in sealed vials requiring reconstitution before use.
Required Materials
- •Retatrutide lyophilized powder (vial)
- •Bacteriostatic water (BAC water) for reconstitution
- •Alcohol swabs (70% isopropyl)
- •1 mL insulin syringe (U-100 for small volumes)
- •Reconstitution syringe (if transferring larger volumes)
Reconstitution Steps
1. Inspect the vial: Verify lyophilized powder is present, vial seal is intact, and the product is within expiry
2. Prepare the work surface: Clean with 70% isopropyl alcohol; allow to dry
3. Swab vial tops: Clean both the retatrutide vial and BAC water vial with alcohol swabs
4. Add bacteriostatic water: Using a syringe, slowly inject BAC water down the side of the vial — do not jet-stream directly onto the powder
5. Gentle mixing: Swirl gently; do not shake (shaking can denature the peptide)
6. Wait for complete dissolution: The solution should become clear. If cloudiness persists, allow to sit for 5–10 minutes then swirl again
7. Label the vial: Note reconstitution date, concentration, and storage conditions
Concentration Calculation
For a 5 mg vial reconstituted with 1 mL BAC water:
- •Concentration = 5 mg/mL = 5,000 μg/mL
- •For a 4 mg research dose: draw 0.8 mL
- •For an 8 mg research dose: draw 1.6 mL (split across two 1 mL syringes if needed)
Storage
- •Unreconstituted: Refrigerate at 2–8°C; protect from light; do not freeze
- •Reconstituted: Refrigerate at 2–8°C; use within 28 days
- •Never: Leave reconstituted peptide at room temperature for extended periods or freeze after reconstitution
For research purposes only. Not for human use.
---
Administration: Subcutaneous Injection Technique
Phase 2/3 trial protocols specify once-weekly subcutaneous injection as the administration route. Research protocols referencing the trial design follow this approach.
Injection Sites (Rotation Required)
Subcutaneous injection sites rotate weekly to prevent tissue irritation and lipodystrophy at administration sites:
- •Abdomen: 2 inches from the navel; avoid the navel itself
- •Anterior thigh: Outer upper thigh (not inner thigh)
- •Upper arm (deltoid region): Outer upper arm (requires assistance for self-administration)
Rotation pattern: Rotate between sites each week. Mark injection sites or keep a log to ensure no site is reused within 2–3 weeks.
Injection Technique
1. Prepare the site: Clean with alcohol swab; allow to dry completely (30 seconds)
2. Prepare the syringe: Draw the required volume; expel air bubbles
3. Pinch technique: Pinch a 1–2 inch fold of subcutaneous tissue at the injection site
4. Insert needle: At 45–90° angle depending on body composition and needle length
5. Inject: Push plunger slowly and steadily
6. Withdraw: Remove needle at same angle; gently press (do not rub) the injection site
7. Dispose: Safely dispose of needle in a sharps container
Timing
Phase 2 trial protocols dosed retatrutide on a fixed weekly schedule (same day each week). Maintaining consistent timing minimizes concentration variability between doses.
For research purposes only. Not for human use.
---
Research Endpoints: Key Efficacy Data
Primary Endpoint: Body Weight Reduction
| Trial Cohort | Baseline BMI (Mean) | Weight Loss at 48 Weeks | Patients Achieving ≥20% Loss |
|---|---|---|---|
| Placebo | ~37 | 2.1% | Not reported |
| 1 mg/week | ~37 | 8.7% | ~16% |
| 4 mg/week | ~37 | 17.1% | ~47% |
| 8 mg/week | ~37 | 22.8% | ~68% |
| 12 mg/week | ~37 | 24.2% | ~83% |
Source: Jastreboff et al., New England Journal of Medicine, 2023
Secondary Endpoints
Glycemic control:
- •Fasting glucose reduction: Up to 8.2 mg/dL reduction (8 and 12 mg cohorts)
- •HbA1c: Not applicable in Phase 2 (population excluded T2DM), but Phase 3 trials are evaluating
Cardiometabolic markers:
- •Triglycerides: Significant reduction across all active dose groups
- •Blood pressure: Meaningful systolic BP reductions at higher doses
- •Waist circumference: Proportional to overall weight loss; >12 cm reduction in 12 mg group
Body composition:
- •Fat mass reduction: Preferential fat loss with lean mass preservation (ratio superior to earlier GLP-1 agents)
These endpoints make retatrutide particularly relevant for researchers studying obesity biology, metabolic syndrome mechanisms, and the interplay between incretin hormones and glucagon signaling.
For research purposes only. Not for human use.
---
Comparison to Semaglutide and Tirzepatide
Understanding retatrutide's place in the research landscape requires comparison with established agents:
| Parameter | Semaglutide (Ozempic) | Tirzepatide (Mounjaro) | Retatrutide (LY3437943) |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max weekly dose | 2.4 mg (obesity) | 15 mg | 12 mg (Phase 3) |
| Phase 2 weight loss | ~14.9% (STEP trials) | ~20.9% (SURPASS trials) | ~24.2% |
| Half-life | ~7 days | ~5 days | ~6–7 days |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
| Approval status | FDA-approved (Wegovy) | FDA-approved (Zepbound) | Phase 3 (investigational) |
| Key differentiator | GLP-1 pioneer | Dual incretin | Triple agonist + thermogenesis |
Mechanistic difference: The glucagon receptor component in retatrutide drives additional thermogenesis and energy expenditure that neither semaglutide nor tirzepatide achieve. This may explain the superior weight loss outcomes at matched durations — the three-receptor synergy creates what researchers describe as "metabolic tripling."
For detailed comparison guides, see:
- •Tirzepatide Dosage Guide: Research Protocol, Reconstitution & Dual GIP/GLP-1 Timing (2026)
- •Semaglutide Dosage Guide: Research Protocol, Reconstitution & Timing (2026)
For research purposes only. Not for human use.
---
Safety Considerations: Phase 2 Adverse Event Profile
Phase 2 trial data provides the most comprehensive safety signal available for retatrutide. Researchers should be aware of the following:
Gastrointestinal Effects (Most Common)
| Adverse Event | 1 mg | 4 mg | 8 mg | 12 mg | Placebo |
|---|---|---|---|---|---|
| Nausea | 15% | 28% | 42% | 47% | 8% |
| Vomiting | 6% | 12% | 18% | 24% | 4% |
| Diarrhea | 10% | 14% | 20% | 25% | 11% |
| Constipation | 8% | 12% | 16% | 17% | 7% |
Timing of GI effects: Peak incidence occurs during dose escalation steps; frequency declines substantially within 2–4 weeks of reaching each new dose level. Gradual escalation is the primary mitigation strategy.
Treatment-Related Discontinuations
- •12 mg cohort: ~16.5% discontinuation rate
- •8 mg cohort: ~9.6% discontinuation rate
- •4 mg cohort: ~3.8% discontinuation rate
Most discontinuations in higher-dose cohorts were GI-related.
Other Notable Adverse Events
- •Heart rate: Modest increase (~3–5 bpm) across active cohorts; mechanism under investigation
- •Injection site reactions: Low incidence (<5%), consistent with class effects
- •Gallbladder events: Class effect for rapid weight loss; incidence reported in Phase 3 monitoring
- •Hypoglycemia: Low risk in non-diabetic populations; more relevant in T2DM cohorts (Phase 3)
Note: The glucagon receptor agonism component raises theoretical concerns about hepatic glucose output; however, Phase 2 data demonstrated net glucose improvement, suggesting GLP-1R and GIPR insulinotropic effects dominate the glucagon effect under physiological conditions.
For research purposes only. Not for human use.
---
Where to Source Retatrutide for Research
For researchers seeking verified retatrutide sourcing information, our comparison platform tracks current supplier availability, purity certifications, and pricing:
Compare Retatrutide Research Suppliers →
When evaluating suppliers for research use, prioritize:
- •Third-party HPLC purity certificates (≥98% preferred)
- •Mass spectrometry verification
- •Certificate of Analysis (COA) from independent labs
- •Transparent sourcing documentation
- •GMP-compliant manufacturing when available
Also see: Best GLP-1 Research Sources 2026 for a curated overview of retatrutide-stocking suppliers.
---
Key Research Citations
1. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389:514-526. DOI: 10.1056/NEJMoa2301972
2. ClinicalTrials.gov NCT04867590 — "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-1)." Eli Lilly and Company. Phase 3.
3. Eli Lilly and Company. Retatrutide (LY3437943) pharmacokinetics and mechanism data. Investor presentations and ENDO 2023 abstracts.
4. Coskun T, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism. 2022;35(6):1086-1099.
---
Summary
Retatrutide (LY3437943) is an investigational triple GLP-1/GIP/glucagon receptor agonist representing the most potent anti-obesity compound in peer-reviewed Phase 2 clinical data as of 2026. Its 24.2% mean body weight reduction at 48 weeks — achieved through the synergistic activation of all three metabolic hormone receptors — distinguishes it from all currently approved agents.
Key research takeaways:
- •Triple mechanism creates superior efficacy vs. dual or single agonists
- •Dose range in trials: 1–12 mg once weekly SC with gradual escalation
- •GI adverse effects are dose-dependent and peak during escalation
- •Phase 3 trials (NCT04867590) ongoing with completion expected 2026–2027
- •Reconstitution with BAC water; refrigerated storage; 28-day post-reconstitution window
For researchers studying metabolic peptides, obesity biology, or next-generation therapeutic candidates, retatrutide's trial data provides a rich dataset for mechanistic studies and comparative research.
---
> ⚠️ Mandatory RUO Disclaimer: All information in this article is for research and educational purposes only. Retatrutide (LY3437943) is an investigational new drug under FDA review. It has not received regulatory approval for any therapeutic indication. This content does not constitute medical advice. Researchers should comply with all applicable institutional, local, national, and international regulations governing the use of investigational compounds. Not for human use.